Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
BioNTech is shutting down manufacturing sites in Germany and Singapore after failing to find buyers. The closures affect up to 1,860 jobs and are part of a broader shift that transfers COVID-19 vaccine production to partner Pfizer. The move marks a significant post-pandemic restructuring for the company that pioneered the West's most widely used COVID vaccine.
BioNTech winds down pandemic-era manufacturing as sale efforts fall flat
BioNTech, the German biotech behind the Western world's most widely used COVID-19 vaccine, is closing manufacturing sites in Germany (Idar-Oberstein, Marburg, and Tübingen) and Singapore after an extensive sales process failed to attract buyers. The company confirmed it worked with its works council to establish "socially responsible solutions" and supplementary redundancy terms for impacted employees.
The closures are part of a broader post-pandemic restructuring in which BioNTech is transferring COVID-19 vaccine production responsibilities to its longtime partner, Pfizer. The company had first announced its intention to sell or wind down these sites back in May 2026. Adding to the leadership shake-up, BioNTech's co-founders are also set to depart by end of 2026 to launch a new venture.
By the Numbers
Why it matters: BioNTech's retreat from pandemic-scale manufacturing signals a broader industry reckoning with post-COVID overcapacity. As demand for COVID vaccines normalizes, companies that rapidly scaled up production are now facing difficult — and costly — decisions about what to do with that infrastructure.
